Blood Substitutes

Marketing application for Hemopure accepted for FDA review

Published in Blood Weekly, November 14th, 2002

Biopure Corporation (BPUR) announced that its Biologic License Application (BLA) for Hemopure [hemoglobin glutamer - 250 (bovine)] has been accepted for review by the U.S. Food and Drug Administration (FDA).

The acceptance is based on the agency's determination that the BLA is adequate to permit a substantive and meaningful review.

On July 31, 2002, Biopure submitted an electronic BLA to the FDA seeking regulatory clearance to market Hemopure in the United States for the treatment of acute anemia in adult patients undergoing orthopedic surgery, and for eliminating or reducing the need for red blood cells in these patients. The application was based...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry